Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

152.65 +1.52 (+1.01%)
Official Closing Price Updated: 7:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
3 Dow Stocks You Can Confidently Buy Now and Hold Forever
These highly profitable, time-tested companies can make their shareholders significantly richer over time. 
Via The Motley Fool
Should Income Investors Buy This Dow Jones Stock?
This drugmaker boasts an impressive product portfolio and pipeline. 
Via The Motley Fool
2 Warren Buffett Stocks to Buy Hand Over Fist and Hold for 30 Years or More
Johnson & Johnson and Apple both have the economic moats and powerful brands that Buffett craves. 
Via The Motley Fool
3 Exceptional Dividend Stocks to Buy Right Now
These stocks can add to your returns -- no matter what the stock itself or the general market is doing. 
Via The Motley Fool
Immunovant Could Potentially Be An M&A Target, Writes Analyst
 
Via Benzinga
JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals
 
Via Benzinga
3 Resilient Stocks to Help Solidify Your Portfolio in 2023
Choose companies with strong fundamentals that can withstand storms and continue to thrive. 
Via The Motley Fool
Worried About 2023? Park Your Money in These 2 Low-Volatility Dividend Stocks
These stocks are low-risk investments with dividends yielding more than 2%. 
Via The Motley Fool
Johnson & Johnson Names Paula A. Johnson, President of Wellesley College, to its Board of Directors
From Johnson & Johnson
Via Business Wire
US Judge Intends To Dismiss Johnson & Johnson's Talc Subsidiary Bankruptcy
A three-judge panel of the Philadelphia-based 3rd U.S. Circuit Court of Appeals ruled to dismiss Johnson & Johnson's (NYSE: JNJ) subsidiary's bankruptcy case regarding talc-related claims. 
Via Benzinga
Johnson & Johnson to Participate in the Barclays Global HealthCare Conference
From Johnson & Johnson
Via Business Wire
Better Buy: Johnson & Johnson or AbbVie?
The healthcare giants are favored by income-oriented investors but have a potentially disruptive year ahead. 
Via The Motley Fool
Acurx is Setting a High Bar for New Treatments in C. diff
A New Gold Standard for C. diff Therapy Could be in the Offing;  Next Data Release Expected in 2Q23 
Via Benzinga
4 Stock Market Sweethearts You'll Want to Call Your Own
It's easy to fall in love with game-changing businesses. 
Via The Motley Fool
Johnson & Johnson Appoints Dr. John Reed as Executive Vice President, Pharmaceuticals, R&D
From Johnson & Johnson
Via Business Wire
3 Supercharged Dividend Stocks to Buy if There's a Stock Market Sell-Off
Income stocks can lend portfolio growth in both up and down markets. 
Via The Motley Fool
3 Warren Buffett Stocks to Buy and Hold
Adding shares of Berkshire Hathaway's top stocks to your equity portfolio could do wonders for your own performance. 
Via The Motley Fool
3 of the Best Dividend Stocks to Buy for February
Despite a decline in popularity recently, dividend stocks are still solid investments and these are some great picks to buy in February. 
Via InvestorPlace
2 Top Stocks to Buy Without Hesitation in 2023
These healthcare giants have a long track record of enriching investors. 
Via The Motley Fool
7 Dividend Stocks to Buy for a Reliable Income Stream
Although the sector isn’t exactly interesting, reliable dividend stocks to buy can keep investors out of trouble while accruing net gains. 
Via InvestorPlace
Strengthen Your Portfolio With These Elite Dividend-Growers
Recently, three new companies were added to the Dividend Aristocrats. That’s a list of the most elite dividend-growing companies in the market. 
Via Talk Markets
A Look At Pharma ETFs Post Q4 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month. 
Via Talk Markets
Pain Relief Medication Market to Witness Huge Growth by Key Players: Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline Plc.
Global Pain Relief Medication Market By Material (Acute, Chronic), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) 
Via SBWire
This Could Cost Johnson & Johnson Billions in Profit
The talc lawsuits create some risk for the business -- but is it enough of a reason to stay away from the stock? 
Via The Motley Fool
3 Dividend Stocks That Will Hold Up No Matter the Market Conditions
These stocks could boost your portfolio in bear markets and bull markets. 
Via The Motley Fool
Is It Time to Buy the Dow Jones' 3 Worst-Performing January Stocks?
They aren't quite the Dogs of the Dow, but these blue chips are limping into February. 
Via The Motley Fool
The 3 Best Forever Stocks to Buy for February 2023
These forever stocks are established companies with great track records that can weather the ups and downs of the market and the economy. 
Via InvestorPlace
Johnson & Johnson's Drug Acquired Via Momenta Deal Shows Encouraging Data In Fetal Disorder
 
Via Benzinga
Why Is Catalent (NYSE:CTLT) Stock Up 20% Today?
Catalent (CTLT) stock is soaring more than 20% in early trading on a report that Danaher was interested in buying CTLT. 
Via InvestorPlace
Johnson & Johnson's Latest Talcum Powder Development Could Be Costly
Johnson & Johnson's pockets could become billions lighter. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.